Get the Stockscreener App
0.4271
7.21%
-0.0332
Pre-market:
.42
-0.0071
-1.66%
Fibrogen Inc Stock (FGEN) Latest News
StockNews.com Initiates Coverage on FibroGen (NASDAQ:FGEN) - Defense World
Weekly CEO Buys Highlight: Camping World, FibroGen - GuruFocus.com
AstraZeneca’s $160 Million Acquisition of FibroGen China - Global Legal Chronicle
Ropes & Gray Advises FibroGen in $160 Million Sale of Fibrogen China to AstraZeneca - Ropes & Gray LLP
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results - The Manila Times
FibroGen, Inc. to Announce Q4 and Full Year 2024 Financial Results on March 17 - Nasdaq
When Will FibroGen Reveal Its 2024 Performance? Key Date for Investors Announced - StockTitan
FibroGen, Inc. to Host Earnings Call - ACCESS Newswire
FibroGen announces $30M "at the market" equity offering - Investing.com India
FibroGen announces $30M "at the market" equity offering By Investing.com - Investing.com South Africa
FibroGen Says Entered ATM Equity Offering Sales Agreement Relating To Sale From Time To Time Of Shares Of Common Stock - Marketscreener.com
Form 424B5 FIBROGEN INC - StreetInsider.com
Asia Deal Watch: AstraZeneca Buys FibroGen’s Chinese Subsidiary - Scrip
FibroGen Inc Announces Sale of China Subsidiary to AstraZeneca f - GuruFocus.com
Investor Network: FibroGen, Inc. to Host Earnings Call - ACCESS Newswire
FibroGen sells China biz to AstraZeneca for $160 M - BSA bureau
FibroGen (FGEN) Expected to Announce Quarterly Earnings on Monday - Defense World
FibroGen sells China unit to AstraZeneca for $160 million - MSN
AstraZeneca Secures China Rights to Anemia Drug, Buying FibroGen Unit in $160M Deal - MSN
Moody's Lifts AstraZeneca's Ratings, Revises Outlook to Stable -February 21, 2025 at 11:51 am EST - Marketscreener.com
FibroGen stock holds $10 target amid China unit sale By Investing.com - Investing.com Nigeria
FibroGen stock holds $10 target amid China unit sale - Investing.com
There's No Escaping FibroGen, Inc.'s (NASDAQ:FGEN) Muted Revenues Despite A 46% Share Price Rise - Simply Wall St
AstraZeneca Buys FibroGen China for $160 Million to Gain Access to Anemia Drug -February 21, 2025 at 03:44 am EST - Marketscreener.com
This Small Cap Soared Following Subsidiary Sale Announcement Worth $160M - The Globe and Mail
FibroGen to sell China business, extend cash runway to focus on cancer drugs - The Business Journals
FibroGen sells China unit to AstraZeneca for $160m - Yahoo Finance
FibroGen (FGEN) to Release Earnings on Monday - MarketBeat
Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million - Benzinga
FibroGen sells China business to AstraZeneca - The Pharma Letter
AstraZeneca boosts China presence with FibroGen's anemia drug in $160 million deal - MSN
AstraZeneca deepens China presence with FibroGen deal - BioPharma Dive
FibroGen’s Strategic Sale and Pipeline Focus Justify Buy Rating Amid Financial Strength - TipRanks
FibroGen Sells Subsidiary to AstraZeneca for $160M - TipRanks
AstraZeneca to buy FibroGen's China unit for $160 million - MSN
FibroGen stock soars on China unit sale By Investing.com - Investing.com South Africa
FibroGen stock soars on China unit sale - Investing.com India
FibroGen soars on $160 mln China unit sale to AstraZeneca - TradingView
FibroGen Sells China Unit to AstraZeneca in $160 Million DealNews and Statistics - IndexBox, Inc.
FibroGen sells China unit to AstraZeneca in deal worth $160 million By Reuters - Investing.com
FibroGen sells China unit to AstraZeneca in deal worth $160 million -February 20, 2025 at 06:40 am EST - Marketscreener.com
FibroGen sells China unit to AstraZeneca for $160 million (FGEN:NASDAQ) - Seeking Alpha
FibroGen Announces Sale of China Subsidiary to AstraZeneca for Approximately $160 Million - Nasdaq
FibroGen sells China unit to AstraZeneca in deal worth $160 million - TradingView
FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million - GlobeNewswire
Inside FibroGen's $160M China Exit: Strategic Pivot or Cash Grab? - StockTitan
Drug developers struggle in 2024; Fibrogen, Acadia, Atai post gains - BioWorld Online
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):